Sunday, April 02, 2017 10:01:08 PM
First NNVC has to come up with a lead candidate that shows promise for curing something. If they can't find a lead candidate, scale-up is a non-issue.
There have been an awful lot of PR's by Seymour claiming to have signed contracts with labs for exactly this purpose of identifying a lead, but every single announced study has so far gone POOF!
Fortunately for Seymour, investors have very short memories:
February 1, 2016 - NanoViricides Signs Agreement with the University of Wisconsin for Testing of Anti-Viral Candidates
http://www.nanoviricides.com/press%20releases/2016/NanoViricides%20Signs%20Agreement%20with%20the%20University%20of%20Wisconsin%20for%20Testing%20of%20Anti-Viral%20Candidates.html
February 11, 2016 - NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the University of Pittsburgh
http://www.nanoviricides.com/press%20releases/2016/NanoViricides%20Signs%20Agreement%20for%20Ocular%20Testing%20of%20Its%20Drug%20Candidates%20for%20the%20Treatment%20of%20Herpes%20Keratitis%20with%20the%20University%20of%20Pittsburgh.html
February 16, 2016 - NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the Baylor College of Medicine
http://www.nanoviricides.com/press%20releases/2016/NanoViricides%20Signs%20Agreement%20for%20Ocular%20Testing%20of%20Its%20Drug%20Candidates%20for%20the%20Treatment%20of%20Herpes%20Keratitis%20with%20the%20Baylor%20College%20of%20Medicine.html
May 31, 2016 - NanoViricides Signs Agreement with St. Jude Children's Research Hospital for further Influenza Drug Development
http://www.nanoviricides.com/press%20releases/2016/NanoViricides%20Signs%20Agreement%20with%20St%20Jude%20Childrens%20Research%20Hospital%20for%20further%20Influenza%20Drug%20Development.html
October 31, 2016 - NanoViricides Signs Agreement with SUNY Upstate Medical Center for Testing of Its Drug Candidates for the Treatment of Shingles
http://www.nanoviricides.com/press%20releases/2016/NanoViricides%20Signs%20Agreement%20with%20SUNY%20Upstate%20Medical%20Center%20for%20Testing%20of%20Its%20Drug%20Candidates%20for%20the%20Treatment%20of%20Shingles.html
There have been an awful lot of PR's by Seymour claiming to have signed contracts with labs for exactly this purpose of identifying a lead, but every single announced study has so far gone POOF!
Fortunately for Seymour, investors have very short memories:
February 1, 2016 - NanoViricides Signs Agreement with the University of Wisconsin for Testing of Anti-Viral Candidates
http://www.nanoviricides.com/press%20releases/2016/NanoViricides%20Signs%20Agreement%20with%20the%20University%20of%20Wisconsin%20for%20Testing%20of%20Anti-Viral%20Candidates.html
February 11, 2016 - NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the University of Pittsburgh
http://www.nanoviricides.com/press%20releases/2016/NanoViricides%20Signs%20Agreement%20for%20Ocular%20Testing%20of%20Its%20Drug%20Candidates%20for%20the%20Treatment%20of%20Herpes%20Keratitis%20with%20the%20University%20of%20Pittsburgh.html
February 16, 2016 - NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the Baylor College of Medicine
http://www.nanoviricides.com/press%20releases/2016/NanoViricides%20Signs%20Agreement%20for%20Ocular%20Testing%20of%20Its%20Drug%20Candidates%20for%20the%20Treatment%20of%20Herpes%20Keratitis%20with%20the%20Baylor%20College%20of%20Medicine.html
May 31, 2016 - NanoViricides Signs Agreement with St. Jude Children's Research Hospital for further Influenza Drug Development
http://www.nanoviricides.com/press%20releases/2016/NanoViricides%20Signs%20Agreement%20with%20St%20Jude%20Childrens%20Research%20Hospital%20for%20further%20Influenza%20Drug%20Development.html
October 31, 2016 - NanoViricides Signs Agreement with SUNY Upstate Medical Center for Testing of Its Drug Candidates for the Treatment of Shingles
http://www.nanoviricides.com/press%20releases/2016/NanoViricides%20Signs%20Agreement%20with%20SUNY%20Upstate%20Medical%20Center%20for%20Testing%20of%20Its%20Drug%20Candidates%20for%20the%20Treatment%20of%20Shingles.html
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
